Home
Arteaus Therapeutics, LLC

Arteaus Therapeutics, LLC Market Share Analysis for June 2026

Industry: N/A

Domainarteaus.com

Year Founded2011

Employees51 - 200

Annual Revenue$15M - $25M

Arteaus Therapeutics, LLC

Arteaus Therapeutics, LLC (including company regionals)

arteaus.com

See more website traffic and engagement information

Arteaus Therapeutics, LLC Revenue up to June 2026 is 15M - 25M

revenue generated by Arteaus Therapeutics, LLC top domains

Arteaus Therapeutics, LLC top domains revenue over 3 years

Revenue for Arteaus Therapeutics, LLC top domains

arteaus.com15M - 25M

See more with Sales Intelligence

Total visits to Arteaus Therapeutics, LLC's top domains

Understand Arteaus Therapeutics, LLC market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Arteaus Therapeutics, LLC's top domains

Analyze Arteaus Therapeutics, LLC engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Arteaus Therapeutics, LLC's top domains

See how Arteaus Therapeutics, LLC keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Arteaus Therapeutics, LLC top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Arteaus Therapeutics, LLC

These are the website technologies, by industry, used by Arteaus Therapeutics, LLC top domains

Domain Parking (1)

Ztomy DNS

Email Services (1)

Rackspace Email

Mobile (1)

Meta Viewport

News & Signals from Arteaus Therapeutics, LLC

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsArteaus sold assets to Royalty Pharma plc in the amount of $260M on Apr 1st '19.Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced today that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company's (NYSE: LLY ) Emgality (galcanezumab), an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for $260 million.